Alembic Pharmaceuticals Ltd
APLLTDAlembic Pharmaceuticals Ltd
APLLTD
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 27.57 | 3.35 | 1.07% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.31 | 5.09 | 0.71% |
Forecast & Ratings
Detailed Forecastfrom 16 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,060.45 | 3,173.11 | 3,107.17 | 3,137.84 | 3,944.06 | 4,610.69 | 5,480.42 | 5,361.53 | 5,655.36 | 6,019.70 | ||||||||||
Raw Materials | 787.42 | 877.07 | 928.05 | 927.62 | 1,084.97 | 1,249.98 | 1,451.27 | 1,489.61 | 1,630.17 | 5,151.22 | ||||||||||
| Power & Fuel Cost | 43.31 | 58.89 | 64.20 | 70.35 | 88.86 | 102.40 | 118.72 | 120.84 | 151.54 | |||||||||||
| Employee Cost | 306.76 | 472.85 | 558.83 | 622.81 | 746.69 | 906.44 | 1,051.17 | 1,133.00 | 1,169.13 | |||||||||||
| Selling & Administrative Expenses | 511.99 | 507.40 | 791.13 | 700.51 | 961.11 | 913.65 | 1,104.03 | 1,354.87 | 1,474.00 | |||||||||||
| Operating & Other expenses | 3.68 | 243.09 | 147.67 | 166.42 | 179.47 | 253.92 | 187.65 | 333.31 | 550.33 | |||||||||||
EBITDA | 407.29 | 1,013.81 | 617.29 | 650.13 | 882.96 | 1,184.30 | 1,567.58 | 929.90 | 680.19 | 868.48 | ||||||||||
| Depreciation/Amortization | 44.41 | 72.21 | 82.97 | 105.46 | 115.23 | 157.32 | 183.48 | 286.78 | 275.43 | 274.37 | ||||||||||
| PBIT | 362.88 | 941.60 | 534.32 | 544.67 | 767.73 | 1,026.98 | 1,384.10 | 643.12 | 404.76 | 594.11 | ||||||||||
| Interest & Other Items | 3.81 | 5.43 | 5.23 | 3.40 | 18.41 | 27.16 | 16.02 | 17.73 | 50.17 | 59.05 | ||||||||||
| PBT | 359.07 | 936.17 | 529.09 | 541.27 | 749.32 | 999.82 | 1,368.08 | 625.39 | 354.59 | 535.06 | ||||||||||
| Taxes & Other Items | 76.15 | 216.12 | 125.93 | 128.64 | 164.95 | 171.00 | 221.58 | 104.45 | 12.60 | 3.38 | ||||||||||
| Net Income | 282.92 | 720.05 | 403.16 | 412.63 | 584.37 | 828.82 | 1,146.50 | 520.94 | 341.99 | 531.68 | ||||||||||
| EPS | 15.01 | 38.20 | 21.39 | 21.89 | 31.00 | 43.97 | 59.55 | 26.50 | 17.40 | 27.05 | ||||||||||
| DPS | 3.50 | 3.50 | 4.00 | 4.00 | 5.50 | 10.00 | 14.00 | 10.00 | 8.00 | 8.00 | ||||||||||
| Payout ratio | 0.23 | 0.09 | 0.19 | 0.18 | 0.18 | 0.23 | 0.24 | 0.38 | 0.46 | 0.30 |
Company Updates
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Alembic Pharmaceuticals Ltd | 42.87 | 3.35 | 1.07% |
| Sun Pharmaceutical Industries Ltd | 34.71 | 4.96 | 0.94% |
| Cipla Ltd | 34.93 | 4.13 | 0.70% |
| Dr Reddy's Laboratories Ltd | 21.38 | 4.14 | 0.69% |
Price Comparison
Compare APLLTD with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Alembic Pharmaceuticals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
DSP Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.4033% | Percentage of the fund’s portfolio invested in the stock 2.35% | Change in the portfolio weight of the stock over the last 3 months -0.18% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/60 (-2) |
Kotak Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.9535% | Percentage of the fund’s portfolio invested in the stock 2.27% | Change in the portfolio weight of the stock over the last 3 months -0.31% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 46/83 (-5) |
DSP Tax Saver Fund - Direct Plan - Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9002% | Percentage of the fund’s portfolio invested in the stock 1.05% | Change in the portfolio weight of the stock over the last 3 months -0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 42/73 (-8) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
APLLTD has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 1.11%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹11.12 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 28, 2023
Dividend/Share
₹8.00
Ex DateEx Date
Jul 28, 2023
Cash Dividend
Ex DateEx DateAug 17, 2022
Dividend/Share
₹10.00
Ex DateEx Date
Aug 17, 2022
Cash Dividend
Ex DateEx DateJul 19, 2021
Dividend/Share
₹14.00
Ex DateEx Date
Jul 19, 2021
Cash Dividend
Ex DateEx DateMar 16, 2020
Dividend/Share
₹7.00
Ex DateEx Date
Mar 16, 2020
Cash Dividend
Ex DateEx DateMar 16, 2020
Dividend/Share
₹3.00
Ex DateEx Date
Mar 16, 2020
News & Opinions
Alembic, Aurobindo recall drugs in US market
3 months ago•Economic Times
Alembic aims for US rebound with new launches
3 months ago•Economic Times
Reduce Alembic Pharma; target of Rs 705: ICICI Securities
3 months ago•Moneycontrol
Broker’s call: Alembic Pharma (Buy)
3 months ago•The Hindu Businessline
Alembic Pharma Q1 Results Review - Execution Remains A Key: Dolat Capital
3 months ago•Bloomberg Quint
Stock to buy today: Alembic Pharmaceuticals (₹732.15)
4 months ago•The Hindu Businessline
Alembic receives USFDA nod for Jarod plant
6 months ago•The Hindu Businessline
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 12.5%, vs industry avg of 8.45%
Increasing Market Share
Over the last 5 years, market share increased from 1.55% to 1.77%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -3.69%, vs industry avg of 9.82%